Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

NACompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 31, 2022

Study Completion Date

December 31, 2022

Conditions
DepressionAnxietyBipolar Disorder
Interventions
DRUG

Escitalopram

Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.

BEHAVIORAL

Cognitive behavioral Psychotherapy

All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.

Trial Locations (2)

45219

University of Cincinnati, Cincinnati

94305-2004

Stanford University, Stanford

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Cincinnati

OTHER

NCT02553161 - Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth | Biotech Hunter | Biotech Hunter